Aminopeptidase A: Could it be a novel target for neurogenic hypertension?

Hypertension

Volumn 51, Issue 5, 2008, Pages 1273-1274

  Ferreira, Anderson J ^a,b   Raizada, Mohan K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN III; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; GLUTAMYL AMINOPEPTIDASE; PRODRUG; PRORENIN; RB 150; UNCLASSIFIED DRUG; VASOPRESSIN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BRAIN; BRAIN BLOOD VESSEL; CARDIOVASCULAR FUNCTION; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; HYPERTENSION; NERVOUS SYSTEM; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR DISEASE;

ANGIOTENSIN II; ANGIOTENSIN III; ANIMALS; BLOOD PRESSURE; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLUTAMYL AMINOPEPTIDASE; HUMANS; HYPERTENSION; RATS; RENIN-ANGIOTENSIN SYSTEM; SULFONIC ACIDS;

EID: 42349101932     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.109561     Document Type: Editorial

References (11)

1. Veerasingham SJ, Raizada MK. Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br J Pharmacol. 2003;139:191-202.
2. Sakai K, Sigmund CD. Molecular evidence of tissue renin-angiotensin systems: a focus on the brain. Curr Hypertens Rep. 2005;7:135-140.
3. Cesari M, Rossi GP, Pessina AC. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J Hypertens. 2002;20:793-799.
4. Wright JW, Tamura-Myers E, Wilson WL, Roques BP, Llorens-Cortes C, Speth RC, Harding JW. Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Am J Physiol. 2003;284:R725-R733.
5. Campagnole-Santos MJ, Heringer SB, Batista EN, Khosla MC, Santos RAS. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol. 1992;263:R89-R94.
6. Wilson WL, Roques BP, Llorens-Cortes C, Speth RC, Harding JW, Wright JW. Roles of brain angiotensins II and III in thirst and sodium appetite. Brain Res. 2005;1060:108-117.
7. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci U S A. 1999;96:13415-13420.
8. Fournie-Zaluski MC, Fassot C, Valentin B, Djordjijevic D, Reaux-Le Goazigo A, Corvol P, Roques BP, Llorens-Cortes C. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proc Natl Acad Sci U S A. 2004;101:7775-7780.
9. Kokje RJ, Wilson WL, Brown TE, Karamyan VT, Wright JW, Speth RC. Central pressor actions of aminopeptidase-resistant angiotensin II analogs: challenging the angiotensin III hypothesis. Hypertension. 2007;49:1328-1335.
10. Bodineau L, Frugière A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, Llorens-Cortes C. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension. 2008;51:1318-1325.
11. Sinnayah P, Lazartigues E, Sakai K, Sharma RV, Sigmund CD, Davisson RL. Genetic ablation of angiotensinogen in the subfornical organ of the brain prevents the central angiotensinergic pressor response. Circ Res. 2006;99:1125-1131.